Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, singlearm study
单位：[1]Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China[2]Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China[3]Tongji Hosp, Tongji Med Coll Huazhong, Wuhan, Hubei, Peoples R China华中科技大学同济医学院附属同济医院[4]Anhui Med Univ, Affiliated Hosp 1, Hefei, Anhui, Peoples R China[5]Zhejiang Univ, Sch Med, Dept Med Oncol, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China[6]Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China[7]307 Hosp, Acad Mil Med Sci, Ctr Canc, Beijing, Peoples R China[8]Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Heilongjiang, Peoples R China[9]China Med Univ, Shengjing Hosp, Shenyang, Liaoning, Peoples R China中国医科大学附属盛京医院中国医科大学盛京医院[10]Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China[11]Fourth Mil Med Univ, Tangdu Hosp, Dept Oncol, Xian, Shaanxi, Peoples R China[12]Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China四川大学华西医院[13]Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China[14]Soochow Univ, Hosp Affiliated 2, Suzhou, Peoples R China[15]Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Guangdong, Peoples R China
Wang Feng,Liu Tian Shu,Yuan Xianglin,et al.Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, singlearm study[J].JOURNAL OF CLINICAL ONCOLOGY.2018,36(15):doi:10.1200/JCO.2018.36.15_suppl.4045.
APA：
Wang, Feng,Liu, Tian Shu,Yuan, Xianglin,Gu, Kangsheng,Yuan, Ying...&Xu, Rui-hua.(2018).Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, singlearm study.JOURNAL OF CLINICAL ONCOLOGY,36,(15)
MLA：
Wang, Feng,et al."Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, singlearm study".JOURNAL OF CLINICAL ONCOLOGY 36..15(2018)
医学